Clinical Rheumatology

, Volume 26, Issue 8, pp 1335–1338 | Cite as

Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis

  • G. Morozzi
  • M. Fabbroni
  • F. Bellisai
  • S. Cucini
  • A. Simpatico
  • M. Galeazzi
Brief Report


The aim of this study was to evaluate serum biomarkers, used in clinical routine, to predict the American College of Rheumatology (ACR) response to long-term anti-TNF alpha treatment (adalimumab). Sera from 29 consecutive rheumatoid arthritis patients were analysed for anti-cyclic citrullinated peptide (anti-CCP), cartilage oligomeric matrix protein (COMP) and IgM and IgA RFs (class-specific rheumatoid factors) at the start of treatment with adalimumab and after 3, 6 and 12 months. The response to the therapy was evaluated by ACR 20, 50, 70 and by DAS 28 scores. The mean serum COMP level of the population did not change after treatment. However, patients with low serum COMP levels (<10 U/l) at baseline showed a significant (p < 0.02) higher ACR70 response (>50%) within 3 months, and also at 6 months, than patients with higher COMP values (ACR70 < 20%). This was also reflected by significantly higher decrease in DAS score at 3 (p < 0.02) and 6 months (p < 0.01) treatments. The IgM RF titre decreased significantly (p = 0.02) after the therapy, but the percentage of serum positivity for anti-CCP and IgA/IgM RF did not change. No significant correlation was shown between serum COMP levels and C-reactive protein/erythrocyte sedimentation rate during the follow-up. Neither were any correlations shown between ACR/DAS 28 scores and anti-CCP, Ig M/IgA RFs. Our data indicate that low (<10 U/l) serum COMP before starting anti-TNF alpha treatment predicts a rapid (within 3 months) and high ACR70 response compared to RA patients with higher COMP values. This might reflect different mechanisms in the cartilage process in the RA disease at that time of treatment with different therapeutic sensitivity to anti-TNF alpha treatment.


Adalimumab Anti-CCP COMP Rheumatoid arthritis Rheumatoid factors 


  1. 1.
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44:2009–2017PubMedCrossRefGoogle Scholar
  2. 2.
    van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weisman M, Weinblatt M, Rau R, Lipsky P (2002) How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 47:215–218PubMedCrossRefGoogle Scholar
  3. 3.
    Saxne T, Mansonn B (2000) Molecular markers for assessment of cartilage damage in rheumatoid arthritis. In: Firestein G, Panayi GS, Wollheim FA (eds) Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Oxford University Press, Oxford, pp 291–304Google Scholar
  4. 4.
    Crnkic M, Mansson B, Larsson L, Geborek P, Heinegard D, Saxne T (2003) Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 5(4):181–185CrossRefGoogle Scholar
  5. 5.
    Roux-Lombard P, Eberhardt K, Saxne T, Dayer JM, Wollheim FA (2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 40(5):544–551CrossRefGoogle Scholar
  6. 6.
    Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64(2):196–201PubMedCrossRefGoogle Scholar
  7. 7.
    Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assay in early rheumatoid arthritis for predicting five years radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRefGoogle Scholar
  8. 8.
    den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P (2002) Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61(4):311–318CrossRefGoogle Scholar
  9. 9.
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:264–272CrossRefGoogle Scholar
  10. 10.
    Skoumal M, Kolarz G, Klingler A (2003) Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol 32(3):156–161PubMedCrossRefGoogle Scholar
  11. 11.
    Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, Situnayake D, Gordon C, Buckley CD, Salmon M, Kitas GD (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32(2):231–238PubMedGoogle Scholar
  12. 12.
    Mikuls TR, O’Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50(12):3776–3782PubMedCrossRefGoogle Scholar
  13. 13.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplfan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  14. 14.
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63(10):1218–1221PubMedCrossRefGoogle Scholar
  15. 15.
    Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26(1):58–62PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  • G. Morozzi
    • 1
  • M. Fabbroni
    • 1
  • F. Bellisai
    • 1
  • S. Cucini
    • 1
  • A. Simpatico
    • 1
  • M. Galeazzi
    • 1
  1. 1.Dipartimento di Medicina Clinica e Scienze Immunologiche-Sezione di ReumatologiaUniversità di Siena-Policlinico Le ScotteSienaItaly

Personalised recommendations